Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis

Ocular Immunology and Inflammation

Volumn 25, Issue 5, 2017, Pages 663-677

  Kam, Ka Wai ^a,b   Chen, Li Jia ^a,b   Wat, Noel ^b   Young, Alvin L ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Allergic conjunctivitis; antihistamine; cornea and external eye; mast cell stabilizer; meta analysis; olopatadine

Indexed keywords

ALCAFTADINE; EPINASTINE; KETOTIFEN; OLOPATADINE; PLACEBO; ANTIALLERGIC AGENT; BENZAZEPINE DERIVATIVE; DIBENZAZEPINE DERIVATIVE; EYE DROPS; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE;

ALLERGIC CONJUNCTIVITIS; ARTICLE; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; OCULAR PRURITUS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; INTRAOCULAR DRUG ADMINISTRATION;

ADMINISTRATION, OPHTHALMIC; ANTI-ALLERGIC AGENTS; BENZAZEPINES; CONJUNCTIVITIS, ALLERGIC; DIBENZAZEPINES; HISTAMINE H1 ANTAGONISTS; HUMANS; IMIDAZOLES; KETOTIFEN; OLOPATADINE HYDROCHLORIDE; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

EID: 84969286343     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2016.1158282     Document Type: Article

References (43)

1. Bogacka E., [Epidemiology of allergic eye diseases]. Pol Merkur Lekarski. 2003;14:714–715.
2. Wan KH, Chen LJ, Rong SS, et al. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology. 2013;120:2197–2203.
3. Butrus S, Portela R., Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am. 2005;18:485–492.
4. McGill JI., A review of the use of olopatadine in allergic conjunctivitis. Int Ophthalmol. 2004;25:171–179.
5. Rosenwasser LJ, O’Brien T, Weyne J., Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin. 2005;21:1377–1387.
6. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996;12:389–400.
7. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996;278:1252–1261.
8. Abelson MB, Shetty S, Korchak M, et al. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opin Pharmacother. 2015;16:1219–1231.
9. Hozo SP, Djulbegovic B, Hozo I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
10. Higgins, JP, Deeks, JJ. Section 7.7.3: Data extraction for continuous outcomes. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. 2011.
11. Higgins, JP, Altman, DG, Sterne, JA; Cochrane Statistical, Methods Group CBMG. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. 2011.
12. Abelson MB, Schaefer K., Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38 Suppl:115–132.
13. Borazan M, Karalezli A, Akova YA, et al. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol (Copenh). 2009;87:549–554.
14. Avunduk AM, Tekelioglu Y, Turk A, et al. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther. 2005;27:1392–1402.
15. Ganz M, Koll E, Gausche J, et al. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. Adv Ther. 2003;20:79–91.
16. Sarker SJ, Chowdhury AN, Hussain Z, et al. Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitis. Therapy. 2011;8:545–553.
17. Berdy GJ, Spangler DL, Bensch G, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 2000;22:826–833.
18. Fukushima A, Ebihara N., Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial. Adv Ther. 2014;31:1045–1058.
19. Fujishima H, Ohashi Y, Takamura E., Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. Ann Allergy, Asthma Immunol. 2014;113:476–481.
20. Mah FS, Rosenwasser LJ, Townsend WD, et al. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin. 2007;23:1445–1452.
21. Lanier BQ, Finegold I, D’Arienzo P, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20:1227–1233.
22. McLaurin EB, Marsico NP, Ackerman SL, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014;31:1059–1071.
23. Ackerman S, D’Ambrosio F Jr, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy. 2013;6:43–52.
24. Greiner JV, Edwards-Swanson K, Ingerman A., Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 min and 16 h after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87–93.
25. Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 2007;28:427–433.
26. Deschenes J, Discepola, M, Abelson M., Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand. 1999;Suppl:47–52.
27. Leonardi A, Abelson MB., Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther. 2003;25:2539–2552.
28. Spangler DL, Bensch G, Berdy GJ., Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001;23:1272–1280.
29. Abelson MB., Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81:211–218.
30. Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther. 2004;26:1237–1248.
31. Greiner JV, Udell IJ., A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2005;27:568–577.
32. Abelson MB, Pratt S, Mussoline JE, et al. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clin Ther. 2003;25:2070–2084.
33. Abelson MB, Welch DL., An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand. 2000;Suppl:60–63.
34. Abelson MB, Spitalny L., Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125:797–804.
35. Scoper SV, Berdy GJ, Lichtenstein SJ, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther. 2007;24:1221–1232.
36. Berger WE., Once-daily olopatadine ophthalmic solution 0.2% in the treatment of allergic conjunctivitis and rhinoconjunctivitis. Expert Rev Pharmacoecon Outcomes Res. 2007;7:221–226.
37. Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol. 2001;86:641–648.
38. Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;6:CD009566.
39. Abelson MB, Turner D., A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Therapeutics. 2003;25:931–47.
40. Butrus S, Greiner JV, Discepola M, et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Therapeutics. 2000;22:1462–72.
41. Kamis U, Ozturk BT, Ozkagnici A, et al. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Acta Ophthalmologica Scandinavica. 2006;84:148–9.
42. Rosenwasser LJ, Mahr T, Abelson MB, et al. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies. 2008;29:644–53.
43. Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmologica Scandinavica. 2003;81:378–82.